MedTrace Logo

OC000459 Bronchial Allergen Challenge

NCT01056692 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-01-26

No results posted yet for this study

Summary

OC0000459 reduces inflammation in the tissues in response to allergic stimuli in patients with asthma. This clinical trial, in mildly asthmatic patients, studies the effects of OC000459 and placebo on the asthmatic response to two known stimulants of the asthmatic response in the lungs, namely cat hair, pollen or house dust mite and methacholine.

Conditions

  • Bronchial Asthma

Interventions

DRUG

OC000459

Capsules twice daily for 15 days

DRUG

Placebo

Capsules twice daily for 15 days

Sponsors & Collaborators

  • Medicines Evaluation Unit, Manchester, UK

    collaborator UNKNOWN

  • King's College Hospital NHS Trust

    collaborator OTHER

  • Oxagen Ltd

    lead INDUSTRY

Principal Investigators

  • David Singh, MD · Medicines Evaluation Unit, Manchester, UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01056692 on ClinicalTrials.gov